CEO Joins the Buying at Quoin, But Price Has Already Run
The COO stepped in earlier today, and now CEO Michael Myers matches it with his own $99,991 into this rare-disease drug developer working on a topical lotion for Netherton syndrome and other orphan skin conditions. That makes four insiders buying in the past 30 days, and a CEO at the top of a cluster signals strength. The catch is the entry. Price sits at $6.51 against Myers' $4.88, money flow is pinned near 98, and RSI is above 68, so you'd be chasing a stock that's already run well past where the insider bought. Let it cool toward that $4.88 zone before you follow him in.
The Filing
| Ticker | QNRX |
| Company | Quoin Pharmaceuticals, Ltd. |
| Insider | Michael Myers, Chief Executive Officer |
| Buy amount | $99,991 |
| Filing date | September 1, 2026 |
| Conviction | Interesting · 62/100 |
| Setup type | Momentum Ride |
Ultimate members received this analysis in real time.